109 related articles for article (PubMed ID: 15624197)
1. Changes in prescribing of inhaled corticosteroids (1999-2002) in Scotland.
Boyter AC; Steinke DT
Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):203-9. PubMed ID: 15624197
[TBL] [Abstract][Full Text] [Related]
2. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
Blais L; Forget A; Ramachandran S
Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
[TBL] [Abstract][Full Text] [Related]
3. Differential prescribing of inhaled corticosteroids in New Zealand general practice.
Hall J; Penrose A; Tomlin A; Reid J
N Z Med J; 2003 Aug; 116(1180):U563. PubMed ID: 14581985
[TBL] [Abstract][Full Text] [Related]
4. Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids.
O'Byrne PM; Rennard S; Gerstein H; Radner F; Peterson S; Lindberg B; Carlsson LG; Sin DD
Respir Med; 2012 Nov; 106(11):1487-93. PubMed ID: 22902134
[TBL] [Abstract][Full Text] [Related]
5. The use of long acting β₂-agonists, alone or in combination with inhaled corticosteroids, in chronic obstructive pulmonary disease (COPD): a risk-benefit analysis.
Cave AC; Hurst MM
Pharmacol Ther; 2011 May; 130(2):114-43. PubMed ID: 21276815
[TBL] [Abstract][Full Text] [Related]
6. Trends in use of inhaled corticosteroids for asthma management: 1994-1998.
Allen-Ramey FC; Samet JM; Rand CS; Joseph CL
Ann Epidemiol; 2004 Mar; 14(3):161-7. PubMed ID: 15036218
[TBL] [Abstract][Full Text] [Related]
7. Safety of inhaled corticosteroids in chronic obstructive pulmonary disease (COPD).
Med Lett Drugs Ther; 2010 May; 52(1339):41-2. PubMed ID: 20508579
[No Abstract] [Full Text] [Related]
8. Trends in the use of inhaled corticosteroids for childhood asthma in New Zealand.
Johansson M; Hall J; Reith D; Jackson P; Tilyard M
Eur J Clin Pharmacol; 2003 Sep; 59(5-6):483-7. PubMed ID: 12937871
[TBL] [Abstract][Full Text] [Related]
9. Differences in the potencies of inhaled steroids are not reflected in the doses prescribed in primary care in New Zealand.
Black PN; Lawrence BJ; Goh KH; Barry MS
Eur J Clin Pharmacol; 2000 Aug; 56(5):431-5. PubMed ID: 11009054
[TBL] [Abstract][Full Text] [Related]
10. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
Lindberg A; Szalai Z; Pullerits T; Radeczky E
Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
[TBL] [Abstract][Full Text] [Related]
11. Effects of corticosteroids on lung function in asthma and chronic obstructive pulmonary disease.
Donohue JF; Ohar JA
Proc Am Thorac Soc; 2004; 1(3):152-60. PubMed ID: 16113428
[TBL] [Abstract][Full Text] [Related]
12. Refill adherence by the elderly for asthma/chronic obstructive pulmonary disease drugs dispensed over a 10-year period.
Krigsman K; Moen J; Nilsson JL; Ring L
J Clin Pharm Ther; 2007 Dec; 32(6):603-11. PubMed ID: 18021338
[TBL] [Abstract][Full Text] [Related]
13. An analysis of the utilisation and expenditure of medicines dispensed for the management of severe asthma.
McGowan B; Bennett K; Barry M; Owens M; O'Connor M
Ir Med J; 2009 Mar; 102(3):73-6. PubMed ID: 19489193
[TBL] [Abstract][Full Text] [Related]
14. A retrospective database study comparing treatment outcomes and cost associated with choice of fixed-dose inhaled corticosteroid/long-acting beta-agonists for asthma maintenance treatment in Germany.
Aballéa S; Cure S; Vogelmeier C; Wirén A
Int J Clin Pract; 2008 Dec; 62(12):1870-9. PubMed ID: 18803555
[TBL] [Abstract][Full Text] [Related]
15. Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): an inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhaler.
Berger WE; Noonan MJ
J Asthma; 2010 May; 47(4):447-59. PubMed ID: 20528601
[TBL] [Abstract][Full Text] [Related]
16. Combination inhalers containing inhaled corticosteroids and long-acting beta2-agonists: improved clinical efficacy and dosing options in patients with asthma.
Ankerst J
J Asthma; 2005 Nov; 42(9):715-24. PubMed ID: 16316864
[TBL] [Abstract][Full Text] [Related]
17. EXCEL: A randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma.
Dahl R; Chuchalin A; Gor D; Yoxall S; Sharma R
Respir Med; 2006 Jul; 100(7):1152-62. PubMed ID: 16675212
[TBL] [Abstract][Full Text] [Related]
18. Onset of effect of budesonide and formoterol administered via one pressurized metered-dose inhaler in patients with asthma previously treated with inhaled corticosteroids.
Kaiser H; Parasuraman B; Boggs R; Miller CJ; Leidy NK; O'Dowd L
Ann Allergy Asthma Immunol; 2008 Sep; 101(3):295-303. PubMed ID: 18814453
[TBL] [Abstract][Full Text] [Related]
19. Trends in hospitalizations and mortality from asthma in Costa Rica over a 12- to 15-year period.
Soto-Martínez M; Avila L; Soto N; Chaves A; Celedón JC; Soto-Quiros ME
J Allergy Clin Immunol Pract; 2014; 2(1):85-90. PubMed ID: 24565774
[TBL] [Abstract][Full Text] [Related]
20. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma.
Aalbers R; Backer V; Kava TT; Omenaas ER; Sandström T; Jorup C; Welte T
Curr Med Res Opin; 2004; 20(2):225-40. PubMed ID: 15006018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
